OMER
Omeros Corporation
NASDAQ · Healthcare · Biotechnology · US
$18.95
−0.84%Aug 13, 2026, 01:05 UTC
Omeros reduced its convertible debt after the quarter ended.
Source:Aug 13, 2026, 01:05 UTC
Omeros reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for TA-TMA, and generated positive operating cash flow.
Source:Aug 13, 2026, 00:00 UTC
Omeros Corporation appointed Joseph Schocken as a director, effective August 12, 2026, and granted him a stock option to purchase 30,000 shares of common stock on the date of appointment.
Aug 12, 2026, 20:02 UTC
Omeros Corporation reported financial results for the second quarter ended June 30, 2026, including gross revenues of $32.2 million from YARTEMLEA, its approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Jun 26, 2026, 18:11 UTC
The European Medicines Agency's expert panel rejected Omeros Corp's primary commercial asset.
Source: